In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will acquire treatment right up until sickness progression or the participants are not able to tolerate the study drugs. There might be greater treatment stress for participants On this trial https://conradc433qcn6.dekaronwiki.com/user